Altogether, NHP2 mRNA levels was not only associated with poor outcome in endometrial cancer independently of the specific therapy in large cohort but also high mRNA levels of NHP2 in diagnostic biopsies distinguish non‐responders from responders to Vistusertib + Anastrozole combination treatment. The gene discussed is NHP2; the disease is endometrial cancer.